Rett syndrome (RTT) is caused by MECP2 mutations, resulting in various neurological symptoms.
Mecp2 deficient mice demonstrate persistently abnormal sodium current (McCauley et al., 2011) ; however, there is no direct metabolic evidence correlating MECP2 mutations and QTc prolongation.
To our knowledge, there are no studies that have evaluated the relationship between QTc and mutation type in RTT. In this study, we investigated QTc in 100 RTT patients, analyzing its relationship to age, clinical severity, and mutation type.
| PATIENTS AND METHODS

| Participants
One hundred MECP2 mutation positive RTT patients were evaluated at the Pediatric Clinical Research Unit of Johns Hopkins Hospital as part of a prospective Natural History study of RTT. Prior to entry into the study, MECP2 mutation analysis was performed by sequencing as described previously (Hoffbuhr et al., 2001) or by commercial laboratories. If sequencing was normal, including exon 1, and the index of suspicion was high, advanced studies were performed at the Greenwood Genetics Center (Greenwood, South Carolina), using multiplex ligation dependent probe amplification analysis to identify large deletions or duplications. Study protocols were approved by the Institutional Review Board at Johns Hopkins Medical Institution, and informed consent was obtained from parents.
| Clinical assessment
To assess clinical severity for each participant at the beginning of the study, standard neurological examinations and a modified version of the Kennedy Krieger Institute Rett Syndrome Severity Scale (RSSS) (Hoffbuhr et al., 2001) were used. The revised RSSS rates seven categories (seizures, gait, scoliosis, respiratory irregularity, hand use, speech, and sleep) on a scale from 0 (normal/absent) to 3 (most severe), and a total score is generated by summing the values (possible values range from 0 to 21) (Table S1 ). Mild clinical severity corresponds to a total score between 0 and 7; moderate clinical severity corresponds to a total score between 8 and 14; and severe clinical severity corresponds to a total score between 15 and 21.
| Electrocardiograms
Standard 12-lead electrocardiograms (ECGs) were obtained at baseline upon entry into the research study. The QT interval was hand measured twice by a single pediatric cardiologist (JB), blinded to clinical severity and genotype, using a standard approach. The observed QT (QTo) was corrected for heart rate by Bazett's correction utilizing the preceding RR 
| Subgroups
Patients were grouped by age groups, clinical severity groups, and genotypes at baseline. Participants were divided into three age groups because of the clinical changes with age as noted previously (Hagberg & Witt-Engerström, 1986; Trevathan & Naidu, 1988) . The first, second, and third groups included patients who were 1 to <7 years old, 7 to <13 years old, and 13 to <19 years old, respectively. Clinical severity groups were based on the RSSS categories of mild, moderate, and severe. The genotypes consisted of each individual common mutation (defined as a missense or nonsense mutation at a position that is affected >1 individual in the sample), small deletions, large deletions, and uncommon mutations (defined as missense or nonsense mutations each of which had a prevalence in our sample of n = 1).
| Data analysis
Data were analyzed using STATA 9.0 (Stata Corporation, College Station, TX). Chi-squared test was used to assess the association between mutation category and having prolonged QTc. Nonparametric Kruskal-Wallis test was used to compare the mean QTc values across the mutation categories. Linear regression model was fit to assess the relationship between QTc and patient characteristics: age and clinical severity (RSSS total score). All statistical tests were two-sided and performed at 5% statistical significance.
3 | RESULTS
| Demographics
The study cohort consisted of 98 females and 2 males. Ages ranged from 1 to 17 years (mean 6.19 ± 3.60 years).
| QTc overview
Among 100 patients, the average QTc was 422.60 ± 21.11 msec. The mean QTc interval overall and for each age group was within normal limits (Table 1) . QTc prolongation occurred in 7 of the 100 patients (7%). The longest QTc of 483 msec was seen in a 7-year-old girl with an R255* mutation ( Figure 1 ). This patient had a composite clinical severity score of 19, in the severe category. She had a family history of long QT syndrome, but in one of her family members who underwent genotyping for genetic variants associated with long QT syndrome, results were negative.
| QTc versus age
With respect to age, QTc prolongation occurred in 3/60 (5%) of patients aged 1 to <7 years, 3/33 (9.1%) of patients aged 7 to <13 years, and 1/7 (14.3%) of patients aged 13 to <19 years. There was a positive relationship between QTc and age after adjusting for total clinical severity score (β = 0.17; 95% confidence interval −0.17 to 2.18), but this linear relationship did not reach statistical significance (P = 0.09). When the data were stratified by clinical severity group, this association between QTc and age was significant for the moderate clinical severity group (linear regression; P = 0.01) but not for mild clinical severity (linear regression; P = 0.98) or severe clinical severity group (linear regression; P = 0.72) (Figure 2 ). Excluding the two male subjects did not affect the statistical significance of these findings.
| QTc versus clinical severity
With respect to clinical severity, QTc prolongation occurred in 0/11 (0%) of mildly affected patients, 4/61 (6.5%) of moderately affected patients, and 3/28 (10.7%) of severely affected patients. There was a positive relationship between QTc and clinical severity score after adjusting age (β = 0.17; 95% confidence interval −0.16 to 2.04), but this linear relationship did not reach statistical significance (P = 0.10).
When the data were stratified by age group, this association between QTc and clinical severity score was significant for the 7 to <13 years age group (linear regression; P = 0.02) but not for the youngest (linear regression; P = 0.85) or oldest age group (linear regression; P = 0.82) ( Figure 3 ). As with QTc versus age, excluding the two male subjects did not affect the statistical significance of these findings.
Interestingly, the two severely affected males in the study, aged 4 years (mutation Q83*) and 6 years (mutation R133C), both had neonatal encephalopathy, respiratory and gastrointestinal compromise, and intermittent bradycardia, but normal QTc. and small deletions (n = 21; 421.7 ± 22.7 msec); however, there was no statistical difference in the QTc distribution across these mutation groups (P = 0.46).
| QTC versus genotype
| Additional factors
Nine patients were taking potentially QTc prolonging medications (see Table 2 ). Of these, only one had QTc prolongation. This patient was taking azithromycin, a potent QTc prolonging agent. In this cohort, there were two known deaths related to aspiration pneumonia but no sudden deaths, though no systematic follow-up data on patient outcomes outside of the study were collected.
| DISCUSSION
We report a lower prevalence of prolonged QTc in RTT patients compared to other studies (Ellaway et al., 1999; Guideri et al., 1999 Guideri et al., , 2001 McCauley et al., 2011; Sekul et al., 1994) . Of the seven patients with prolonged QTc, one had a family history of prolonged QTc (without identified etiology on genetic testing) and another was on a potentially QTc prolonging medication, leaving five with no known predisposition. The ECG measurements in our cohort are likely valid based on the following two lines of reasoning. First, all ECGs were performed on an outpatient basis, during periods of relative stability for the patients. Second, each QT interval was hand-measured twice by an experienced pediatric cardiologist. One possible explanation for the relatively lower prevalence of QTc prolongation in our cohort is the age distribution; there were only three individuals (all female) >14 years old. Girls 14-18 years-old generally have greater QTc intervals compared to boys (Pearl, 1996) , and hence this age group was underrepresented in our sample compared to other studies in RTT patients.
The second finding of this report is that there was a positive (particularly the mild clinical severity group and oldest age group as shown in Figures 2-3 ), this analysis in these groups may be underpowered and potentially more data points may be needed before a definite conclusion is drawn whether the positive linear relationships are limited to certain subgroups. In the literature, data is mixed regarding the association of prolonged QTc with age and clinical severity in RTT. In one study, patients with classic RTT had lower heart rate variability and longer QTc compared to patients with the preserved speech variant RTT (Guideri et al., 2001) . In two studies, QTc prolongation significantly correlated with advancing clinical stages of the syndrome (Guideri et al., 1999; Sekul et al., 1994) , whereas another study found no correlation with either clinical stage or age (Ellaway et al., 1999) . Hence, there is need for a large scale prospective longitudinal cohort study to determine the precise relationship between QTc and age/severity.
The final finding of this report is that there was no genotype which predicted QTc prolongation. One explanation is that perhaps there is an association, but a larger number of individuals in each mutation are needed for an effect to become apparent. Another possibility is the presence of non-genetic/epigenetic factors (such as health status) modulating the QTc interval. Our study, though limited, is the first to demonstrate no relationship of specific mutations in MECP2 with QTc prolongation in RTT.
In RTT, the significance of QTc prolongation in relation to sudden death remains unknown, but one possible explanation pertains to induction of life threatening arrhythmias. Some investigators suggest that the sudden deaths in these patients may be due to long QTc related ventricular arrhythmias McCauley et al., 2011) . However, the prevalence of such arrhythmias seems to be low (Acampa & Guideri, 2006) ; in one study, out of 214 patients with RTT who underwent ECG screening, there was only one individual who had findings of ventricular tachycardia preceding sudden death . Moreover, there is very little published data about sudden deaths in RTT patients, including information on related biochemical, electrophysiological, or pathological changes.
Though human data on QTc and sudden death in RTT is lacking,
there is relevant animal model data that offer more insight. Mice with a
Mecp2 deletion specific to the nervous system had an age-related increase in the QTc and had a high incidence of inducible ventricular arrhythmias during programmed electrical stimulation (McCauley et al., 2011) . Since the ventricular tachycardia induced in these mice by programmed stimulation was actually monomorphic and not polymorphic, the correlation with long QT, which is characterized by polymorphic torsade de pointes (Bhandari et al., 1985) , is unclear, and actually suggests another mechanism of sudden death, such as alterations in sympathetic tone, known to exist in RTT (Acampa et al., 2008; Guideri et al., 2001 , Guideri, Acampa, Hayek, & Zappella, 2005 Rohdin et al., 2007; Weese-Mayer et al., 2008) . Sympathetic disturbances have also been associated with QTc prolongation in other disease states (Asai et al., 2007) .
The mild degree of QTc prolongation in RTT patients seen by us and by other investigators (Ellaway et al., 1999; Guideri et al., 1999 Guideri et al., , 2001 McCauley et al., 2011; Sekul et al., 1994) does not support a direct causal relationship between prolonged QTc and sudden death in RTT. However, one can speculate that poor heart rate variability and autonomic dysfunction, combined with seizure activity possibly acutely prolonging the QTc interval, could create a "perfect storm"
to increased susceptibility to ventricular arrhythmia and sudden cardiac death. In support of this notion is data that secondarily generalized tonic-clonic seizures, the predominant type of epilepsy in RTT syndrome, can lead to persistent tachycardia and abnormal QTc shortening (Surges, Scott, & Walker, 2010) . Therapy to prevent sudden death in these patients thus may need to include management of issues other than the QTc, especially in the area of autonomic dysfunction. The findings of an antiarrhythmic effect of phenytoin but not propranolol in the RTT mouse model (Herrera et al., 2015; McCauley et al., 2011) and that chronic oral acetyl-L carnitine administration in RTT patients can improve heart rate variability are noteworthy. Moreover, according to a retrospective analysis, RTT patients treated with anticonvulsants which block Na + channels demonstrated improvements in QT interval (Herrera et al., 2015) .
In terms of clinical surveillance, screening for prolonged QTc with ECG should be part of the initial evaluations after a diagnosis of RTT (Christodoulou & Ho, 1993) . We recommend a detailed family history in all RTT patients with observed QTc prolongation to exclude a possible inherited cause, along with a thorough review of the 
